2025
Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks
Kawiková I, Špička V, Lai J, Askenase P, Wen L, Kejík Z, Jakubek M, Valeš K, Španiel F. Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks. Frontiers In Immunology 2025, 16: 1454306. PMID: 40264776, PMCID: PMC12011847, DOI: 10.3389/fimmu.2025.1454306.Peer-Reviewed Original ResearchConceptsDevelopment of immune therapiesEVs-based therapyIatrogenic immune deficienciesRobust preclinical dataExploitation of extracellular vesiclesPsychiatric diseasesDiagnostic biomarker panelExtracellular vesiclesRecipient cell functionsImmune therapyImmune deficiencyPatient subsetsPreclinical dataFluid abnormalitiesBiomarker panelEV administrationImmune systemIntercellular communicationPrecision therapeuticsTherapyTherapeutic toolCell functionRegulatory approvalPsychiatric conditionsBrain regions
2024
Rare Drivers at Low Prevalence with High Cancer Effects in T-Cell and B-Cell Pediatric Acute Lymphoblastic Leukemia
Mandell J, Diviti S, Xu M, Townsend J. Rare Drivers at Low Prevalence with High Cancer Effects in T-Cell and B-Cell Pediatric Acute Lymphoblastic Leukemia. International Journal Of Molecular Sciences 2024, 25: 6589. PMID: 38928295, PMCID: PMC11203805, DOI: 10.3390/ijms25126589.Peer-Reviewed Original ResearchGenomic analysisPediatric acute lymphoblastic leukemiaCancer effectsAcute lymphoblastic leukemiaT cellsTherapeutic targetSomatic substitutionsRare driversB-ALLLymphoblastic leukemiaEpistatic effectsT-cell ALL patientsMutational contributionsMutated genesCancer phenotypeMutated formDevelopment of leukemiaLow prevalenceB-cell lineageDisease mechanismsMutationsPrecision therapeuticsTherapeutic opportunitiesT-ALLALL patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply